Abstract
Studies in osteosarcoma over the past 40 years have led to a steady improvement in the overall outcome of patients with osteosarcoma. In the year 2008, we can expect greater than 60% overall survival for newly diagnosed non-metastatic appendicular osteosarcoma. However, to achieve this current outcome, many patients are treated with aggressive cytotoxic chemotherapy and ultimately are not cured, and some patients who would be curable even without this aggressive approach are likely treated and cured. And finally, patients presenting with metastatic disease and those whose tumors recur after standard approaches continue to do very poorly. We believe that in order to continue to make progress in the treatment of this disease, we must achieve two main objectives. Firstly, we must find biomarkers that prospectively and accurately identify newly diagnosed non-metastatic patients who will not be cured with current modalities.
We hope that the achievement of this goal will allow for innovative clinical studies in this high-risk population while not jeopardizing those patients who currently are cured using the available treatment approaches, and ultimately accelerate progress toward curing more patients. Secondly, we must develop entirely new approaches to the treatment of metastatic and recurrent osteosarcoma. Our approach has been to develop models of highly aggressive and less aggressive osteosarcoma, and to use these models to identify genetic alterations and signaling pathways that distinguish the two phenotypic behaviors. We have identified plasma membrane-cytoskeletal linker protein, ezrin, as one pathway that identifies aggressive biological behavior in mouse and dog osteosarcoma. Using ezrin as the initial discriminator, we have high ezrin expression to activation of mTOR signaling, suggesting a possible novel target for therapy of aggressive osteosarcoma. We have also linked β4 integrin signaling to metastatic behavior that also appears to be linked to mTOR signaling. Most recently, we have identified a critical relationship between mTOR signaling and the IGF I signaling pathway that may help point the way to combination targeting therapy aimed at blocking both mTOR and IGF signaling in these tumors. Finally, we have proposed a novel clinical trial design to begin to test agents targeted at recurrent, metastatic disease, and this also will be discussed.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Dahlin DC, Coventry MB. Osteogenic sarcoma: a study of six hundred cases. J Bone Joint Surg Am. 1967;49A:101-110.
Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2002;20:776-790.
Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004-2011.
Kempf-Bielack B, Bielack SS, Jurgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005;23:559-568.
Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet. 2003;145:1-30.
Keith WN, Evans TRJ, Glasspool RM. Telomerase and cancer: time to move from a promising target to a clinical reality. J Pathol. 2001;195:404-414.
Savage SA, Stewart BJ, Liao JS, et al. Telomere stability genes are not mutated in osteosarcoma cell lines. Cancer Genet Cytogenet. 2005;160:79-81.
Ulaner GA, Huang HY, Otero J, et al. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res. 2003;63:1759-1763.
Sanders RP, Drissi R, Billups CA, et al. Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol. 2004;22:3790-3797.
Strahm B, Malkin D. Hereditary cancer predisposition in children: genetic basis and clinical implications. Int J Cancer. 2006;119:2001-2006.
Wadayama BI, Toguchida J, Shimizi T, et al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res. 1994;54:3042-3048.
Feugeas O, Guriec N, Babin-Boilletot A, et al. Loss of heterozygosity in the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol. 1996;14:467-472.
Heinsohn S, Evermann U, Stadt UZ, et al. Determination of the prognostic value of loss of heterozygosity at the retinoblastoma gene in osteosarcoma. Int J Oncol. 2007;30:1205-1214.
Wunder JS, Gokgoz N, Parkes R, et al. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol. 2005;23:1483-1490.
Wang LL. Biology of osteogenic sarcoma. Cancer J. 2005;11:294-305.
Nishijo K, Nakayama T, Aoyama T, et al. Mutation analysis of the RECQL4 gene in sporadic osteosarcomas. Int J Cancer. 2004;111:367-372.
Pollak M, Sem AW, Richard M, et al. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst. 1992;84:966-971.
Pollak M, Polychronakos C, Richard M. Insulin like growth factor I: a potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst. 1990;82:301-305.
Burrow S, Andrulis IL, Pollak M, et al. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol. 1998;69:21-27.
Mansky PJ, Liewehr DJ, Steinberg SM, et al. Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of Insulin-like Growth Factor-1 serum levels. J Pediatr Hematol Oncol. 2002;24:440-446.
Yeatman TJ. A renaissance for Src. Nat Rev Cancer. 2004;4:470-480.
Webb DJ, Donais K, Whitmore LA, et al. FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol. 2004;6:154-161.
Azuma K, Tanaka M, Uekita T, et al. Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcoma. Oncogene. 2005;24:4754-4764.
Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91-100.
Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004;10:182-186.
Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006;5:671-688.
Chawla SP, Sankhala KK, Chua V, et al. A phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas. J Clin Oncol. 2005;23(suppl):9068.
Chawla SP, Tolcher AW, Staddon AP, et al. Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. J Clin Oncol. 2006;24(suppl):9505.
Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 2005;65:2406-2411.
Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-56.
Laverdiere C, Hoang BH, Yang R, et al. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res. 2005;11:2561-2567.
Perissinotto E, Cavalloni G, Leone F, et al. Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res. 2005;11:490-497.
Kim SY, Lee CH, Midura BV, et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis. 2008;25:201-211.
Bacci G, Briccoli A, Longhi A, et al. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol. 2005;44:748-755.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Kim, S.Y., Helman, L.J. (2009). Strategies to Explore New Approaches in the Investigation and Treatment of Osteosarcoma. In: Jaffe, N., Bruland, O., Bielack, S. (eds) Pediatric and Adolescent Osteosarcoma. Cancer Treatment and Research, vol 152. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-0284-9_31
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0284-9_31
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-0283-2
Online ISBN: 978-1-4419-0284-9
eBook Packages: MedicineMedicine (R0)